Company Info
Phone(617) 600-7373
Year Established
2007
Ticker
NERV
Exchange
NASDAQ
Contacts
Cynthia BamdadCEO & CSO
Ron Axelrod
COO
Company Description
Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.